2019 Buprenorphine and Medication Assisted Treatment (MAT) Train the Trainer (TTT) Program
June 9-10, APA Headquarters, Washington, DC
The American Psychiatric Association (APA), in partnership with the Providers Clinical Support System (PCSS), is proud to announce the 2019 Buprenorphine and Medication Assisted Treatment (MAT) Train the Trainer (TTT) Program.
The Buprenorphine and MAT TTT Program is a two-day training hosted in Washington, DC that offers an in-depth training to DEA-X waivered psychiatrists who are currently prescribing buprenorphine to patients and are interested in serving as a regional buprenorphine trainer.
The program aims to expand the network of local buprenorphine trainers nation-wide, increase the number of buprenorphine trainings, and expand the number of buprenorphine-waivered providers to increase access to MAT.
This year’s program will be held from June 9-10, 2019 at the APA main office in Washington, DC. APA will provide travel and accommodations for all TTT program participants in accordance with APA travel policies. All applicants are required to submit a letter of support from their respective district branch outlining plans for their first training and how they plan to secure funding.
The deadline to apply for the TTT program is Friday, April 29, 2019.
There is no fee to apply or participate in the TTT program. Visit the Buprenorphine and MAT TTT program website to learn more eligibility and application requirements. Please contact Rachel Trusty at email@example.com for additional questions.
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.